# Radiopharmaceuticals Sector

Canonical URL: https://biopharmsignal.com/sector/radiopharmaceuticals

Radiopharmaceuticals includes companies pairing radioactive payloads with targeted delivery approaches for imaging or treatment, especially in oncology. It is a closely watched category because it combines precision targeting with differentiated procedural and therapeutic economics.

Companies currently grouped under Radiopharmaceuticals: 4

## Recent Sector News

- 2026-10-07 10:16 EST — CATX — [Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-212pb-vmt-net-data-for-presenta-805861cd) — Source: Perspective Therapeutics
- 2026-10-02 15:46 EST — CATX — [Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-212pb-vmt01-data-for-presentati-1aa0ca2a) — Source: Perspective Therapeutics
- 2026-09-14 10:16 EST — CATX — [Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-w-ae67c0c5) — Source: Perspective Therapeutics
- 2026-09-11 10:00 EST — CATX — [Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for  Presentation at the 38th EORTC-NCI-AACR Symposium 2026](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-vmt-net-data-for-presentation-a-23082677) — Source: Perspective Therapeutics
- 2026-08-10 20:22 EST — CATX — [Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results](https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-4479e0c1) — Source: Perspective Therapeutics
- 2026-07-31 10:30 EST — CATX — [Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-provide-business-highlights-and-report-second-quarte-9488302c) — Source: Perspective Therapeutics
- 2026-07-28 10:30 EST — CATX — [Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs](https://biopharmsignal.com/news/CATX/perspective-therapeutics-receives-european-orphan-medicinal-product-designation--6620bea5) — Source: Perspective Therapeutics
- 2026-07-17 16:22 EST — CATX — [Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-vmt-net-data-for-oral-presentat-0e2c17aa) — Source: Perspective Therapeutics
- 2026-07-08 10:30 EST — CATX — [Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor](https://biopharmsignal.com/news/CATX/perspective-therapeutics-appoints-paul-lyne-ph-d-as-chief-science-officer-co-fou-463c2453) — Source: Perspective Therapeutics
- 2026-06-03 10:30 EST — CATX — [Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study](https://biopharmsignal.com/news/CATX/perspective-therapeutics-expands-therapeutic-focus-areas-first-patient-dosed-wit-a2195748) — Source: Perspective Therapeutics
- 2026-05-21 21:51 EST — CATX — [Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma](https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-present-data-from-all-clinical-programs-at-the-2026--e41c812b) — Source: Perspective Therapeutics
- 2026-05-18 10:30 EST — CATX — [Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-first-patients-dosed-in-new-cohorts-of-two-on-f86856dd) — Source: Perspective Therapeutics
- 2026-05-11 20:07 EST — CATX — [Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results](https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-1q-2026-51d96ebf) — Source: Perspective Therapeutics
- 2026-04-24 10:30 EST — CATX — [Perspective Therapeutics to Provide Several Upcoming Corporate Updates](https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-provide-several-upcoming-corporate-updates-8b1db0ef) — Source: Perspective Therapeutics
- 2026-04-20 10:00 EST — CATX — [Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/CATX/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-net-in-its-o-7075427d) — Source: Perspective Therapeutics
- 2026-04-02 11:00 EST — CATX — [Perspective Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-participate-in-upcoming-investor-conferences-64fada5b) — Source: Perspective Therapeutics
- 2026-03-17 20:45 EST — CATX — [Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-acceptance-of-vmt-net-data-for-presentation-a-48b35ba8) — Source: Perspective Therapeutics
- 2026-03-16 20:07 EST — CATX — [Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results](https://biopharmsignal.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-full-ye-0c9211ff) — Source: Perspective Therapeutics
- 2026-02-17 12:00 EST — CATX — [Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results](https://biopharmsignal.com/news/CATX/perspective-therapeutics-to-provide-business-highlights-and-report-full-year-202-fa8cd9c9) — Source: Perspective Therapeutics
- 2026-02-02 13:35 EST — CATX — [Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/CATX/perspective-therapeutics-announces-pricing-of-175-million-underwritten-offering--01927356) — Source: Perspective Therapeutics

## Companies

- [FUSN](https://biopharmsignal.com/company/FUSN) — Fusion Pharmaceuticals Inc.
- [LNTH](https://biopharmsignal.com/company/LNTH) — Lantheus Holdings, Inc.
- [CATX](https://biopharmsignal.com/company/CATX) — Perspective Therapeutics
- [RYZB](https://biopharmsignal.com/company/RYZB) — RayzeBio